Previous 10 | Next 10 |
home / stock / azncf / azncf news
2024-06-21 14:31:06 ET Summary Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. P...
2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...
2024-06-15 10:58:09 ET Summary As expected, AstraZeneca's price has increased in the past quarter, and by a notable 18.4%, following a robust Q1 2024 performance. Recent approvals in the US market, earlier attractive market multiples and a dividend increase also supported the stoc...
2024-06-11 11:25:13 ET Summary The BlackRock Enhanced International Dividend Trust offers attractive geographical diversification and a high level of income with a yield of 7.28%. The BGY closed-end fund's lower yield compared to similar funds appears to be partly due to its less ...
2024-06-09 05:15:00 ET Summary Structure Therapeutics raises $476 million through an offering of its ADSs after announcing positive clinical results for its obesity drug. Suzhou Alphamab Oncology partners with ArriVent BioPharma to develop antibody drug conjugates, potentially rec...
2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...
2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...
2024-05-30 09:14:24 ET Summary Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032...
2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...
2024-05-24 07:00:00 ET Summary AstraZeneca reported Q1 2024 earnings of $12.7bn, up 19% YoY, and EPS of $2.06, up 13% YoY. The company aims to achieve $80bn in total revenue by 2030, up from $45.8bn in 2023. AZN plans to launch 20 new medicines by 2030, many with the potential...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...